CanaQuest Medical Corp Overview
– a clinical-stage life sciences company
CanaQuest Medical (CANQF), a clinical-stage, life sciences company, is focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and PPAR receptors. The Company is prioritizing treating neurological conditions such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder “PTSD,” including addiction.
Preclinical Trials were conducted by Dr. Steven Laviolette, a professor, and neuroscientist, with decades of experience in the field of mental health and cannabinoids, at Western University. The trials demonstrated: decreased: anxiety, depression, PTSD, schizophrenia, opioid addiction, and decreased inflammation in the brain.
Clinical Studies for epilepsy were conducted at the Ontario Brain Institute by Dr. W McIntyre Burnham, emeritus professor at the University of Toronto. The studies compared Drug Candidate, CQ-001, to standard CBD, and demonstrated 50% more seizure reduction.
Synergistic Effect:
Cannabidiol combined with essential fatty acids (omega-3s) enhances penetration into the brain.
Pharmaceutical:
CQ-001 – Drug candidate formula of two APIs – cannabidiol “CBD” + essential fatty acids
- Molecules bond and synergistically attach to PPAR receptors allowing CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and NOTE: CBD by itself DID NOT do this in their pre-clinical trial research.
CQ-001 demonstrated statistically significant Clinical Dose & Efficacy Study (“Study”) results as described above.
- These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (Phase II/III, double-blind trial, 60 patients).
Health Canada: Eligible for Priority Review Status – projected approval of a drug is 24 months.
US-FDA: Eligible for Orphan Drug Status & Priority Review Voucher (PRV) – projected approval in 3 years.
Nutraceutical:
An OTC (less potent version, different format) of CQ-001, branded as Mentanine®, targeting anxiety, depression, and PTSD will be utilized to conduct clinical studies.
Neeka Health: The Company signed a Master Service Agreement with Neeka Health which will encompass multiple studies on former professional athletes. The Neeka team has conducted extensive due diligence on over 100 companies in the cannabinoid space, and CanaQuest was the only company chosen. Neeka was founded by Dr. Amin Kassam, a world-renowned neurosurgeon.
Dr. Hunter Land, CSO of Neeka, who co-led the clinical development of Epidiolex® (FDA-approved prescription CBD) for GW Pharma will lead all studies for Neeka and CanaQuest.
NHL Alumni Association:
The Company signed an agreement with the objective of Neeka conducting clinical studies on former NHL hockey players to evaluate the effect of Mentanine® on anxiety, mental clarity, quality of life, and feeling of overall health and well-being.
Advisory Board:
Dr. Paul Dick, Paul Dick & Associates. has agreed to be the Chairman of the Advisor Board, including the development of our pharmaceutical business, and subsequently advising on veterinary regulatory strategies to obtain approvals from regulatory authorities.
CanaQuest has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical Awards by Global Health & Pharma, UK.
Private Placement:
The Company is having discussions.
Please reach out to learn more.
Paul Ramsay, CEO & Co-founder
Dir: 416-704-3040
paul@canaquest.com
www.canaquest.com
